China Animal Vaccine Industry Report, 2019-2025
  • Feb.2020
  • Hard Copy
  • USD $3,600
  • Pages:173
  • Single User License
    (PDF Unprintable)       
  • USD $3,400
  • Code: ZLC097
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $5,000
  • Hard Copy + Single User License
  • USD $3,800

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized basis. As estimated, the animal vaccine market would plummet by 5.4% and stand at RMB11.2 billion in 2019.

Meanwhile, the demand for poultry meat, beef and mutton rises steadily, so does the vaccines for poultry, cattle and sheep. As ASF vaccines are anticipated to be available on the market in 2020 and the quantity of live hogs picks up, the hog vaccine market will bottom out and begin to rise in the upcoming years, being expectedly worth RMB17.18 billion in 2025.

In China, animal vaccines are mainly for hogs, poultry, cattle and sheep. Yet, the hog vaccine market plunged as a result of the African Swine Fever, triggering an estimated market share down to 28.3% in 2019 when the poultry vaccines would hold a share up to 39.1%. 

Animal vaccines fall into the vaccines used for compulsory vaccination and the market-oriented vaccines in China, where the former covers the diseases such as highly pathogenic avian influenza, aftosa, peste des petits ruminants (PPR), Brucellosis, and hydatidosis. Porcine Reproductive and Respiratory Syndrome (PRRS) and hog cholera started to be excluded from compulsory vaccination in 2017, which is conductive to the more lucrative market-priced vaccines for animals.

Chinese animal vaccine industry is currently dominated by homegrown companies like Jinyu Bio-technology, China Animal Husbandry Industry Co., Ltd.(CAHIC), Qingdao Yebio Biological Engineering Co., Ltd. (Yebio), Tecon Biology, Keqian Biology, Ringpu Bio-technology, and Pulike Biological Engineering. Among them, Jinyu Bio-technology is the largest producer of animal vaccines in China, with its revenue in 2018 reporting RMB1,845.5 million and enjoying a 15.6% share of the domestic animal vaccine market.

动物疫苗 EN_副本.png

In addition, the broad prospects of Chinese animal vaccine industry draws attention from foreign companies like MSD and Boehringer Ingelheim, and they have made inroads in the Chinese market through joint ventures, acquisitions and sole proprietaries.

China’s animal vaccines are heading towards:
i.) The growing concentration of the industry: Chinese animal vaccine producers are now faced with huge overcapacity, low capacity utilization and serious homogenization of products. Some leading Chinese players have staged mergers and acquisitions successively to be more competitive. The industry concentration is on a steady rise.
ii.) New products facilitate the development of the industry: In 2018, there were a total of 71 new veterinary drugs in China, including 22 registrations of vaccine new veterinary drugs or a 31% share. The roll-out of vaccine new veterinary drugs is expected to boost the development of the animal vaccine industry;
iii.) African Swine Fever brings growth potential: A nosedive in the quantity of live hogs since the outbreak of the African Swine Fever in China in August 2018 leads to a tumble in the hog vaccine market. Breakthroughs have been made by China in vaccination for African Swine Fever. In October 2019, China first isolated the structure of the ASF virus, and pilot production of the ASF vaccine has been fulfilled. The vaccine will be ratified and launched to the market in 2020, significantly invigorating the hog cholera vaccine market.

China Animal Vaccine Industry Report, 2019-2025 highlights the followings:
20120114.gifAnimal vaccine market in China and beyond (market size & structure, import & export, competitive landscape and development tendencies);
20120114.gifEnvironments (policy climate and social environment) for the development of China’s animal vaccine industry;
20120114.gifAnimal vaccine market segments in China;
20120114.gif16 Chinese animal vaccine companies (operation, revenue structure, gross margin, R&D costs, animal vaccine business, etc.)

1. Overview of Animal Vaccine
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Status Quo of Animal Vaccine Industry
2.1 Global Market
2.1.1 Market Size
2.1.2 Market Structure
2.1.3 Competitive Landscape
2.2 Chinese Market
2.2.1 Market Size
2.2.2 Market Structure
2.2.3 Import and Export
2.2.4 Entry Barriers
2.2.5 Competitive Landscape
2.2.6 Trends

3. Development Environment for China Animal Vaccine Industry
3.1 Policy Environment
3.1.1 Major Policies
3.1.2 Tendering System for Compulsory Immunization Vaccine
3.2 Social Environment
3.2.1 Stable Development of Farming Industry
3.2.2 Large-scale Farming Becomes a Trend
3.2.3 Frequent Outbreaks of Animal Epidemics

4. Chinese Animal Vaccine Industry Segments
4.1 Governmental Mandatory Vaccine
4.1.1 FMD Vaccine
4.1.2 Bird Flu Vaccine
4.2 Market-oriented Vaccine
4.2.1 Swine Fever Vaccine
4.2.2 PRRS Vaccine
4.2.3 PCV Vaccine
4.2.4 Newcastle Disease Vaccine
4.2.5 Pet Vaccine

5 Key Enterprises
5.1 China Animal Husbandry Industry Co., Ltd. (CAHIC)
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.1.5 R & D
5.1.6 Animal Vaccine Business
5.2 Jinyu Bio-technology
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 R & D
5.2.6 Animal Vaccine Business
5.2.7 Forecast and Outlook
5.3 Tecon Biology
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 R&D
5.3.6 Clients and Suppliers
5.3.7 Animal Vaccine Business
5.3.8 Forecast and Outlook
5.4 Tech-bank Food
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 R&D
5.4.6 Animal Vaccine Business
5.5 Hugeleaf
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.5.5 R&D
5.5.6 Animal Vaccine Business
5.6 Ringpu Bio-technology
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 R & D
5.6.6 Animal Vaccine Business
5.7 Hile Bio-Technology
5.7.1 Profile
5.7.2 Operation
5.7.3 Revenue Structure
5.7.4 Gross Margin
5.7.5 R&D
5.7.6 Animal Vaccine Business
5.8 Pulike Biological Engineering, Inc.
5.8.1 Profile
5.8.2 Operation
5.8.3 Revenue Structure
5.8.4 Gross Margin
5.8.5 R&D
5.8.6 Animal Vaccine Business
5.9 Shen Lian Biomedical
5.9.1 Profile
5.9.2 Operation
5.9.3 Revenue Structure
5.9.4 Gross Margin
5.9.5 R&D
5.9.6 Clients and Suppliers
5.9.7 Animal Vaccine Business
5.10 Keqian Biology
5.10.1 Profile
5.10.2 Operation
5.10.3 Revenue Structure
5.10.4 Gross Margin
5.10.5 R&D
5.10.6 Animal Vaccine Business
5.11 Winsun Bio-Pharmaceutical
5.11.1 Profile
5.11.2 Operation
5.11.3 Revenue Structure
5.11.4 Clients and Suppliers
5.11.5 R&D
5.11.6 Animal Vaccine Business
5.12 Other Enterprises
5.12.1 Yikang Biological
5.12.2 Weike Biotechnology
5.12.3 Nannong Hi-Tech
5.12.4 Sinopharm Animal Health
5.12.5 Wens Dahuanong

6. Summary and Forecast
6.1 Summary
6.2 Market Segments
6.2.1 Swine Vaccine
6.2.2 Poultry Vaccine
6.2.3 Cattle and Sheep Vaccine
Classification of Animal Health Products
Animal Vaccine Types (by Constituent and Feature) and Characteristics
Animal Vaccine Industry Chain
Classification of Animal Epidemics in China
Global Veterinary Biological Product Market Size and YoY Change, 2010-2025E
Global Animal Vaccine Consumption Structure, 2018
Major M&A Events in Global Animal Health Industry, 2005-2019
Profile of Global Animal Health Products Giants
Chinese Animal Vaccine Market Size and YoY Change, 2013-2019
Chinese Animal Vaccine Market Structure (by Applied Type), 2017-2019
China’s Animal Vaccine Import and Export Volume, 2009-2019
China’s Average Animal Vaccine Import and Export Prices, 2009-2019
China’s Animal Vaccine Import Sources (by Import Value), Jan.-Nov. 2019
China’s Animal Vaccine Export Destinations (by Export Value), Jan.-Nov.2019
Main Regions Which Import Animal Vaccines and Their Share in Import Volume in China, Jan.-Nov.2019
Main Regions Which Export Animal Vaccines and Their Share in Export Volume in China, Jan.-Nov.2019
Number of Veterinary Vaccine Companies in China, 2009-2017
Major Chinese Animal Vaccine Manufacturers, 2018
Comparison of Major Chinese Animal Vaccine Manufacturers: Revenue, Net Income and Gross Margin in 2018
Competitive Landscape of China Animal Vaccine Industry, 2018
Main Cases of Foreign Companies’ Arrangements in Chinese Animal Vaccine Industry, 2018-2019
Production Capacity and Capacity Utilization of Chinese Animal Vaccine Companies, 2009-2018
Mergers and Acquisitions in Chinese Animal Vaccine Industry
Number of the New Veterinary Drugs Registered in China, 2014-2018
Classification of the New Veterinary Drugs Registered (by Application) in China, 2018
New Drug Approval of Major Chinese Animal Vaccine Companies, 2018-2019
The Quantity of Live Hogs and Sows in China, 2018-2019
Capacity Reduction in Provinces/Municipalities in China as of July 25, 2019
Statistical Table for African Swine Fever Epidemic and Deblocking of the Infected Areas in China as of January 16, 2020
Progress in Research of Candidate Vaccine for African Swine Fever and Efficacies
China’s ASF Vaccine R&D Results as of October 2019
Major Polices on China Animal Vaccine Industry, 2010-2019
Compulsory Immunization Plan of Animal Epidemics in China, 2020
Animal Diseases worth Priority Prevention in China, 2012-2020
Defects of China’s Compulsory Immunization Tender System
Direction for China’s Compulsory Immunization Tender System Reform
Output of Meat, Eggs and Milk in China, 2009-2019
China’s Meat Product Structure (by Output), 2011-2019
Quantity Structure (%) of Live Hog Breeding Farms of Varied Scale in China, 2007-2017
Quantity Structure (%) of Broiler Breeding Farms of Varied Scale in China, 2007-2017
Overview of Common Animal Epidemics in China
China’s Animal Vaccine Market Structure (by Sales Method)
Development Process of Chinese Compulsory Vaccination Policies
Usage of Vaccines by Small and Medium-sized Live Pig Farmers by Product in China (%)
Winning Prices of Main Animal Vaccines in China, 2018
Market Shares of Governmental Mandatory Vaccines and Market-oriented Vaccines in China, 2013-2019
The Frequency of Publicized Aftosa Epidemic by China, 2011-2018
Chinese Aftosa Vaccine Market Size, 2016-2019
Main Aftosa Vaccines and Brands in China
Chinese Aftosa Vaccine Market Structure (by Enterprise), 2017
Chinese Poultry Vaccine Market Structure (by Type), 2013-2017
Spring Tendering for Avian Influenza Vaccines in Some Provinces/Municipalities in China, 2018-2019
Information about Chinese Manufacturers of Recombinant Avian Influenza Virus (H5+H7) 3-valent Inactivated Vaccine
Tender-based Prices of 3-valent Inactivated Avian Influenza Vaccine in Some Provinces, China
Chinese Hog Cholera Vaccine Market Structure (by Type), 2013-2017
History of Compulsory Vaccination for Hog Cholera in China
Structure of Vaccines Used by Chinese Farmers (by Type)
Number of the Producers of Hog Cholera Vaccines (by Variety) in China
Product Categories of Main Chinese Hog Cholera Vaccine Producers
Chinese PRRS Vaccine Market Size Estimation, 2015 vs.2020
Comparison of Main Chinese PRRS Vaccine Companies by Strength
China’s Total Output (China-made & Imported) of Porcine Circovirus Type 2 Vaccine, 2015-2019
Porcine Circovirus Vaccines and Major Manufacturers
Porcine Circovirus Type 2 Vaccine under Clinical Trial in 2018
Main Newcastle Disease Combined Vaccines of Chinese Animal Vaccine Companies
Age Structure of Pet Keepers in China, 2018
Pet Population in China, 2018 (by Type, Units in Ten Thousand)
Market Size of Vaccines for Pets and Others in China, 2017-2025E
Subsidiaries and Branches of CAHIC
Controlling Shareholders of CAHIC
CAHIC’s Revenue and Net Income, 2009-2019
CAHIC’s Revenue Breakdown by Product, 2011-2018
CAHIC’s Revenue Structure by Product, 2011-2018
CAHIC’s Output, Sales Volume and Inventory, 2016-2018 (10k ml/10k doses, ton)
CAHIC’s Revenue (by Region), 2011-2018
CAHIC’s Revenue Structure (by Region), 2011-2018
Gross Margin of CAHIC’s Main Products, 2011-2018
CAHIC’s R & D Costs and % of Total Revenue, 2011-2018
CAHIC’s Animal Vaccine Subsidiaries and Their Products
Net Income of Major Animal Vaccine Subsidiaries of CAHIC, 2018-2019H1
Revenue from and Gross Margin of Veterinary Vaccines of CAHIC, 2011-2018
Revenue from Foot-and-Mouth Disease Vaccine of CAHIC, 2016-2018
CAHIC’s Varieties/Output/Sales Volume of and Revenue/Net Income from Main Veterinary Vaccines, 2018
Winning Prices of CAHIC’s Veterinary Vaccines, 2018
JinyuBio-technology’s Revenue and Net Income, 2009-2019
Jinyu Bio-technology’s Revenue (by Product), 2011-2018 (Unit: RMB mln)
Gross Margin of Jinyu Bio-technology’s Main Business, 2010-2018
Jinyu Bio-technology’s R & D Costs and % of Total Revenue, 2011-2018
Animal Vaccine Subsidiaries of Jinyu Bio-technology, 2018
Jinyu Bio-technology’s Output/Sales Volume/Inventory of Main Vaccines, 2018
Jinyu Bio-technology’s Revenue from and Gross Margin of Vaccines, 2011-2015
Main Reserve Vaccines of Jinyu Bio-technology
Revenue and Net Income of Jinyu Baoling, 2012-2019
Assets and Net Income of Yangzhou Uni-Bio Pharmaceutical, 2012-2019
Jinyu Bio-technology’s Revenue and Net Income, 2015-2020E
Tecon’s Revenue and Net Income, 2009-2019
Tecon’s Revenue (by Product), 2011-2018
Tecon’s Revenue Structure (by Product), 2011-2018
Tecon’s Revenue (by Region), 2011-2019
Tecon’s Revenue Structure (by Region), 2011-2019
Gross Margin of Tecon’s Main Products, 2011-2018
Tecon’s R&D Costs and % of Total Revenue, 2011-2019
Tecon’s Revenue from Top 5 Clients and % of Total Revenue, 2011-2018
Tecon’s Procurement from Top 5 Suppliers and % of Total Procurement, 2011-2018
Tecon’s Animal Vaccine Production Bases and Capacity, 2015
Animal Vaccines under Research and Progress of Tecon
Tecon’s Sales of Animal Vaccines, 2016-2018
Revenue and Gross Margin of Animal Vaccines of Tecon, 2011-2018
Tecon’s Revenue and Net Income, 2015-2020E
Tech-bank’s Revenue and Net Income, 2009-2019
Tech-bank’s Revenue (by Product), 2017-2019
Tech-bank’s Revenue (by Region), 2011-2019
Tech-bank’s Revenue Structure (by Region), 2011-2019
Tech-bank’s Gross Margin of Main Products, 2016-2019
Tech-bank’s R&D Costs and % of Total Revenue, 2011-2019
Revenue and Net Income of Animal Vaccines of Chengdu Tech-bank, 2016-2019
Hugeleaf’s Revenue and Net Income, 2009-2019
Hugeleaf’s Revenue (by Product), 2011-2018
Hugeleaf’s Revenue Structure (by Product), 2011-2018
Hugeleaf’s Revenue (by Region), 2011-2018
Hugeleaf’s Revenue Structure (by Region), 2011-2018
Gross Margin of Hugeleaf’s Main Products, 2011-2018
Hugeleaf’s R&D Costs and % of Total Revenue, 2011-2018
Revenue and Net Income of Qingdao Yebio Biological Engineering, 2012-2019
Ringpu Bio-technology’s Revenue and Net Income, 2009-2019
Ringpu Bio-technology’s Revenue (by Product), 2011-2018
Ringpu Bio-technology’s Revenue Structure (by Product), 2011-2018
Ringpu Bio-technology’s Revenue (by Region), 2012-2018
Ringpu Bio-technology’s Revenue Structure (by Region), 2012-2018
Ringpu Bio-technology’s Gross Margin of Main Products, 2011-2018
Ringpu Bio-technology’s R & D Costs and % of Total Revenue, 2011-2018
Varieties of Animal Vaccines Launched by Ringpu Bio-technology, 2014-2019
Ringpu Bio-technology’s Animal Vaccine Output and Sales Volume (by Product), 2011-2018
Sales and Gross Margin of Ringpu Bio-technology’s Animal Vaccines (by Product), 2013-2018
Ringpu Bio-technology’s Animal Vaccine Subsidiaries and Their Operation, 2018
Ringpu Bio-technology’s Animal Vaccines with New Veterinary Drug Approval Number, 2018-2019
Ringpu Bio-technology’s New Animal Vaccines with New Veterinary Drug Registration Certificate, 2018-2019
Progress in the Ongoing Animal Vaccine Projects of Ringpu Bio-technology as of June 2019
Hile Bio’s Main Products
Hile Bio’s Revenue and Net Income, 2011-2019
Hile Bio’s Revenue Structure (by Product), 2011-2016
Hile Bio’s Revenue Structure (by Product), 2017-2018
Hile Bio’s Revenue (by Region), 2011-2017
Hile Bio’s Revenue (by Region), 2018
Gross Margin of Hile Bio’s Main Products, 2011-2016
Hile Bio’s R & D Costs and % of Total Revenue, 2011-2018
Hile Bio’s Main Animal Vaccines under Development and Investment, 2018
Hile Bio’s Revenue Structure (by Sales Model), 2017-2018
Hile Bio’s Output, Sales Volume and Inventory of Veterinary Biological Products, 2017-2018
Bid Winning of Hile Bio’s Animal Vaccines in the Centralized Drug Tender Procurement, 2018
Hile Bio’s Animal Vaccine Fundraising Projects, 2014
Major Holding and Joint-stock Subsidiaries of Pulike, 2018
Main Animal Vaccines of Pulike
Pulike’s Revenue and Net Income, 2012-2019
Sales Model and Revenue of Pulike, 2014-2018
Pulike’s Revenue (by Product), 2012-2018
Pulike’s Revenue Structure (by Product), 2012-2018
Gross Margin of Pulike’s Main Products, 2012-2018
Pulike’s R & D Costs and % of Total Revenue, 2011-2019
Animal Vaccine Output, Sales Volume, and Inventory of Pulike, 2018
Output and Sales Volume of Pulike’s Main Animal Vaccines, 2018
Revenue and Gross Margin of Pulike’s Animal Vaccines, 2012-2018
Pulike’s Investments in R&D OF Main Animal Vaccines, 2018
Revenue and Net Income of Shanghai Shen Lian Biomedical, 2016-2019
Revenue Structure (by Product) of Shanghai Shen Lian Biomedical, 2019H1
Revenue Structure (by Region) of Shanghai Shen Lian Biomedical, 2016-2019H1
Gross Margin of Shanghai Shen Lian Biomedical, 2016-2019
Shanghai Shen Lian Biomedical’s R&D Costs and % of Total Revenue, 2016-2019
Top Five Customers of Shanghai Shen Lian Biomedical, 2016-2019
Top Five Suppliers of Shanghai Shen Lian Biomedical, 2016-2019
Revenue Structure (by Sales Model) of Shanghai Shen Lian Biomedical, 2016-2019H1
Quantity Tender and Qualification Tender Winning of Shanghai Shen Lian Biomedical, 2016-2019
Sales Volume (by Product) of Shanghai Shen Lian Biomedical, 2016-2019
Capacity Utilization and Production & Sales of Shanghai Shen Lian Biomedical, 2016-2019
Development Course of Wuhan Keqian Biology
Revenue and Net Income of Wuhan Keqian Biology, 2016-2019
Operating Revenue (by Product) of Wuhan Keqian Biology, 2016-2019H1
Operating Revenue Structure (by Product) of Wuhan Keqian Biology, 2016-2019H1
Operating Revenue (by Region) of Wuhan Keqian Biology, 2016-2019H1
Operating Revenue Structure (by Region) of Wuhan Keqian Biology, 2016-2019H1
Gross Margin (by Product) of Wuhan Keqian Biology, 2016-2019
Wuhan Keqian Biology’s R&D Costs and % of Total Revenue, 2016-2019
Revenue Structure (by Sales Model) of Wuhan Keqian Biology, 2016-2019H1
Average Selling Price and Sales Volume of Main Vaccines of Wuhan Keqian Biology, 2016-2019
Wuhan Keqian Biology’s Revenue from and Sales Volume of Top Five Products, 2016-2019
Capacity Planning of Wuhan Keqian Biology’s Animal Biological Product Industrialization Project
Animal Vaccine Capacity, Output and Sales Volume of Wuhan Keqian Biology, 2016-2019
Production Lines of Wuhan Keqian Biology
Revenue and Net Income of Guangdong Winsun Bio-Pharmaceutical, 2014-2019
Revenue (by Product) of Guangdong Winsun Bio-Pharmaceutical, 2014-2018
Revenue Structure (by Product) of Guangdong Winsun Bio-Pharmaceutical, 2014-2018
Revenue Structure (by Region) of Guangdong Winsun Bio-Pharmaceutical, 2018
Guangdong Winsun Bio-Pharmaceutical’s Revenue from Top5 Clients, 2014-2018
Guangdong Winsun Bio-Pharmaceutical’s Procurement from Top5 Suppliers, 2014-2018
Guangdong Winsun Bio-Pharmaceutical’s R&D Costs and % of Total Revenue, 2014-2018
Animal Vaccine Business Development of Winsun Bio-Pharmaceutical, 2018-2019
Chinese Animal Vaccine Market Size and YoY Change, 2013-2025E
Chinese Animal Vaccine Market Structure (by Animal Attributes), 2025
Chinese Swine Vaccine Market Size, 2013-2025E
Chinese Poultry Vaccine Market Size, 2013-2025E
Chinese Cattle and Sheep Vaccine Market Size, 2017-2025E

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号